The Pharmaceutical Managers Institute

thepmi.com

The PMI is a professional membership organisation dedicated to the continuous learning, development and support of those working in management within the pharmaceutical industry. Our membership is diverse, covering Commercial, Marketing, Market Access, Product Management and Regulatory roles; representating over 80 pharmaceutical organisations.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INNOVATION PHARMACEUTICALS GRANTS INTELLECTUAL PROPERTY AND COMMERCIALIZATION RIGHTS TO FOX CHASE CHEMICAL DIVERSITY FOR ANTIFUNGAL TECHNOLOGY

Innovation Pharmaceuticals, Fox Chase Chemical Diversity Center | July 23, 2020

news image

Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, announces today that the Company and Fox Chase Chemical Diversity Center, Inc. have amended an earlier collaborative research agreement related to antifungal drug discovery work. Under the amended terms, and in exchange for a six (6) percent fee tied to all potential future proceeds—including upfront payments, milestone payments and royalties—the Company is granting FCCDC all discovery, intellectua...

Read More

PHARMACY MARKET

SANOFI'S HOPES FOR RARE BLOOD DISEASE CANDIDATE SUTIMLIMAB ON HOLD AFTER FDA BLASTS 3RD-PARTY MANUFACTURER

Sanofi | November 17, 2020

news image

When a new drug goes in front of the FDA for consideration, a lot of moving pieces must be in place for a successful review—manufacturing standards included. That didn't happen for Sanofi, which is pressing pause on a rare disease candidate after the FDA found issues at a contract manufacturer's plant. The FDA blasted a third-party manufacturer of Sanofi's rare blood disease drug sutimlimab in a complete response letter, citing "certain deficiencies" at...

Read More

AMARIN ANNOUNCES PLANS TO MAXIMIZE BLOCKBUSTER POTENTIAL OF VASCEPA® IN EUROPE

Amarin spurns | August 05, 2020

news image

Amarin's wild 2020 ride continues. Tuesday, the company said COVID-19 took a bite out of second quarter earnings, and it unveiled plans to launch its fish-oil derivative drug Vascepa in Europe without help from a bigger marketing partner. And that's on top of prepping for federal court this fall, where it will try to salvage Vascepa's key patents. Amarin positioned its European plans as a positive: It did receive multiple proposals from potential partners. But the significant sales o...

Read More

BUSINESS INSIGHTS

COLUBRISMX, INC. ANNOUNCES CORPORATE REBRANDING TO ENDOQUEST ROBOTICS™

ColubrisMX | July 01, 2022

news image

ColubrisMX, Inc., developer of the world's first flexible endoluminal robotic system which enables scar-free and less invasive surgical procedures, announced that the Company has rebranded to ENDOQUEST Robotics™. The Company also announced the simultaneous launch of its new website, www.endoquestrobotics.com. "Since being founded, our company has made rapid progress in the development of technologies that represent historic advances in endolumi...

Read More
news image

INNOVATION PHARMACEUTICALS GRANTS INTELLECTUAL PROPERTY AND COMMERCIALIZATION RIGHTS TO FOX CHASE CHEMICAL DIVERSITY FOR ANTIFUNGAL TECHNOLOGY

Innovation Pharmaceuticals, Fox Chase Chemical Diversity Center | July 23, 2020

Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, announces today that the Company and Fox Chase Chemical Diversity Center, Inc. have amended an earlier collaborative research agreement related to antifungal drug discovery work. Under the amended terms, and in exchange for a six (6) percent fee tied to all potential future proceeds—including upfront payments, milestone payments and royalties—the Company is granting FCCDC all discovery, intellectua...

Read More
news image

PHARMACY MARKET

SANOFI'S HOPES FOR RARE BLOOD DISEASE CANDIDATE SUTIMLIMAB ON HOLD AFTER FDA BLASTS 3RD-PARTY MANUFACTURER

Sanofi | November 17, 2020

When a new drug goes in front of the FDA for consideration, a lot of moving pieces must be in place for a successful review—manufacturing standards included. That didn't happen for Sanofi, which is pressing pause on a rare disease candidate after the FDA found issues at a contract manufacturer's plant. The FDA blasted a third-party manufacturer of Sanofi's rare blood disease drug sutimlimab in a complete response letter, citing "certain deficiencies" at...

Read More
news image

AMARIN ANNOUNCES PLANS TO MAXIMIZE BLOCKBUSTER POTENTIAL OF VASCEPA® IN EUROPE

Amarin spurns | August 05, 2020

Amarin's wild 2020 ride continues. Tuesday, the company said COVID-19 took a bite out of second quarter earnings, and it unveiled plans to launch its fish-oil derivative drug Vascepa in Europe without help from a bigger marketing partner. And that's on top of prepping for federal court this fall, where it will try to salvage Vascepa's key patents. Amarin positioned its European plans as a positive: It did receive multiple proposals from potential partners. But the significant sales o...

Read More
news image

BUSINESS INSIGHTS

COLUBRISMX, INC. ANNOUNCES CORPORATE REBRANDING TO ENDOQUEST ROBOTICS™

ColubrisMX | July 01, 2022

ColubrisMX, Inc., developer of the world's first flexible endoluminal robotic system which enables scar-free and less invasive surgical procedures, announced that the Company has rebranded to ENDOQUEST Robotics™. The Company also announced the simultaneous launch of its new website, www.endoquestrobotics.com. "Since being founded, our company has made rapid progress in the development of technologies that represent historic advances in endolumi...

Read More